Drugs / 1PC002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01710007 | Nov 2011 → Sep 2012 | hyperlipoproteinemia | Orient Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1PC002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01710007 ↗ |
| Action | Inhibit | “HMG-CoA reductase inhibitor” NCT01710007 ↗ |
| Modality | Small molecule | “newly developed synthetic and highly potent HMG-CoA reductase inhibitor” NCT01710007 ↗ |
| Route | Oral | “orally once a day” NCT01710007 ↗ |